USE OF FAS LIGAND TO SUPPRESS ARTHRITIS

描述：几个小组的初步报告表明， 基于Fas配体的治疗预防移植排斥反应的潜力， 治疗自身免疫性疾病，诱导免疫耐受和治疗 癌Fas配体抑制T淋巴细胞介导的免疫反应 响应”受美国专利No.5，759，536保护，Donald Bellgrau和 Richard C.杜克发明家CERES Pharmaceuticals已获得该技术的许可 来自科罗拉多大学。本SBIR第一阶段的总体目标 应用程序是在一个完善的小鼠模型中开发和测试， 关节炎，商业化重组腺病毒基因治疗载体 编码具有增强的治疗潜力的突变形式的Fas配体。 这些载体及其生产和应用策略， 人类类风湿性关节炎（美国专利申请中）将被授权 制药和/或生物技术公司用于提交研究性申请 新药（IND）申请与FDA在预期的I期临床 人类的足迹 拟议商业应用：不可用

DESCRIPTION: Preliminary reports by several groups have demonstrated the potential for Fas ligand-based therapy to prevent transplant rejection, to treat autoimmune disease, to induce immunological tolerance and to treat cancer. The "Use of Fas Ligand to Suppress T-lymphocyte mediated Immune Responses" is protected by U.S. Patent No. 5,759,536, Donald Bellgrau and Richard C. Duke, Inventors. CERES Pharmaceuticals has licensed this Technology from the University of Colorado. The overall goal of this Phase I SBIR application is to develop and test in a well-established mouse model of arthritis, commercially-useful recombinant adenoviral gene therapy vectors encoding mutated versions of Fas ligand with enhanced therapeutic potential. These vectors and strategies for their production and application to treat human rheumatoid arthritis (U.S. Patents Pending) will be licensed to Pharmaceutical and/or Biotechnology companies for use in filing Investigational New Drug (IND) Applications with the FDA in anticipation of phase I clinical trails in humans. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE